Wednesday, May 29, 2019 DrugName : rituximab
Chugai Pharmaceutical Co., Ltd. announced that the Tokyo District Court has rendered judgment dismissing the plaintiff’s claim in the lawsuit filed by Genentech Inc., wherein the plaintiff demands prohibition against sales etc. of the biosimilar product of anti-CD20 monoclonal antibody Rituxan® Intravenous Infusion 100 mg and 500 mg (Rituxan Intravenous Infusion) by Sandoz K.K. and Kyowa Hakko Kirin Co., Ltd., citing such parties’ infringement of three use patents owned by Biogen Inc., as the ground.
Chugai and Zenyaku Kogyo Co., Ltd. have been assisting intervention in the lawsuit.
[sg_popup id=”2993″ event=”hover”][/sg_popup]Biogen is a holder of those patents and Genentech Inc. is the exclusive licensee. Zenyaku Kogyo is the exclusive distribution rights’ holder in Japan of Rituxan Intravenous Infusion, and Chugai is the joint distributor of Rituxan Intravenous Infusion with Zenyaku Kogyo.
There is no impact expected on Chugai’s financial prospects for this matter at this stage.
Trademarks used or mentioned in this release are protected by law.
Key Facts
Legal And Regulatory
Other Product News
Product Development
Hectic lifestyle, tight work schedules, pressure canadian cialis no prescription at work, and stressfulness in personal life are some factors to affect the muscle tissue and blood vessels which supports in adequate blood supply to the sexual organs and men enjoy firmer and harder erection. The Staff’s Dilemma and Responsibility From birth to age six, kids’ brains are particularly responsive to experiential viagra sale australia influence. buy levitra from canada When taken before planned sexual activity. Use of herbal semen quantity supplement can be brand viagra from canada see description described as the efficient one that bears the inheriting work ability to stimulate and develop the risks of humiliation in the bed.
Asia-Pacific > Japan
North America > United States of America